Building a commercial dream team for today ’s pharma industry
Nearly three years since COVID-19 abruptly forced pharmaceutical commercialization teams to adopt fully digital engagement models, the industry has adjusted to a more complex and diverse mix of engagement modalities.Pharma is adapting to this hybrid engagement model along with a host of other changes to engagement strategies by rethinking the makeup of commercialization teams and the skills that they prioritize.In many ways the rep ’s role has become more complex. There is a growing requirement for them to connect the right decision-makers at the provider with the right subject matter experts in pharma. In addition, flex...
Source: EyeForPharma - December 7, 2022 Category: Pharmaceuticals Authors: Brian Eastwood Source Type: news
How Neuromyelitis Optica Progressed for Me
A woman with NMO and a doctor who treats it talk about what it’s like to live with the rare disease. (Source: WebMD Health)
Source: WebMD Health - December 2, 2022 Category: Consumer Health News Source Type: news
Big names, big dollars back Mahzi, a Peninsula drug startup targeting rare genetic brain disorders
The 10-employee company, including veterans of rare disease drug developer Ultragenyx Pharmaceutical, has gathered $47.3 million. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 29, 2022 Category: American Health Authors: Ron Leuty Source Type: news
Alexion's new U.S. head is looking for 'the next generation of medicines to unpack'
A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 22, 2022 Category: American Health Authors: Rowan Walrath Source Type: news
Looking Beyond Clinical Trials for Mesothelioma Treatment
Clinical trial results should not always be the guiding force when a mesothelioma cancer patient and their medical team determine what therapy path to take, according to one recent study. A look at real-world populations might be just as important.
A research team at the University of Pennsylvania Department of Medicine has made the point with a retrospective, observational analysis of second-line treatment for pleural mesothelioma.
The analysis came on the heels of a multicenter clinical trial from the European Thoracic Oncology Platform that evaluated the efficacy of pembrolizumab (Keytruda), an immunotherapy drug,...
Source: Asbestos and Mesothelioma News - November 22, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
